September 26th 2024
Your daily dose of the clinical news you may have missed.
Sildenafil Boosts the Heart's Performance, Too
July 12th 2007EDMONTON, Alberta -- Phosphodiesterase type 5 (PDE5) drugs, such as sildenafil (Viagra), may improve right ventricular contractility in hearts with right ventricular hypertrophy, an unexpected benefit that looks promising for treatment of right ventricular heart failure.
Preventing pulmonary embolism with vena caval filters
July 1st 2007* Vena caval interruption has been used in the treatment of deep venous thrombosis (DVT) to prevent PE since the early 1970s. Filter placement has been increasing in the past decade. We estimate that filters are placed in more than 0.2% of all Medicare recipients annually.
Heart Failure: Part 1, Diagnosis and Staging
July 1st 2007Heart failure is prevalent in both primary care and cardiology practices. It develops in about 1 in 5 persons during their lifetime and in about 1 in 8 of those who have not sustained a myocardial infarction (MI). Heart failure is also the leading cause of hospitalization in the elderly.
Ventricular Tachycardia in Acute Myocardial Infarction
July 1st 2007A 67-year-old woman arrived via ambulance in ventricular tachycardia. She had been experiencing crushing substernal chest pain and shortness of breath that had worsened over the past several hours. She received oxygen (by mask) and lidocaine (100 mg intravenously) en route to the emergency department (ED), but there was no change in the rhythm.
ADA: Avandia Critic Meets Skeptical Diabetologists
June 26th 2007CHICAGO -- When the spotlight here focused on rosiglitazone (Avandia) and its harshest critic, Steven E. Nissen, M.D., of the Cleveland Clinic, the cardiologist offered a mild apology to a room full of diabetologists for complicating their lives.
FDA Orders New Safety Labels for Roseglitazone (Avandia) and Pioglitazone (Actos)
June 6th 2007WASHINGTON -- FDA Commissioner Andrew C. von Eschenbach, M.D., today told a congressional hearing that the FDA will beef up the cardiovascular warnings on the labels of both rosiglitazone (Avandia) and pioglitazone (Actos).
Cardiac Mortality Drop Attributed to Therapies and Risk Factor Reductions
June 6th 2007ATLANTA -- Credit for the near halving of the rate of coronary disease deaths in the U.S, from 1980 to 2000, belongs equally to reductions in risk factors and to the rise of evidence-based therapies, found CDC and British researchers.
BREAKING NEWS: British Analysis Does Not Confirm Rosiglitazone (Avandia) MI Risk
June 5th 2007NEWCASTLE UPON TYNE, England, June 5 -- An interim analysis of the 4,447-patient RECORD trial did not confirman increased risk of myocardial infarction or cardiac death in patients taking rosiglitazone (Avandia) for treatment of type 2 diabetes, although the data suggest an increased risk of heart failure. So reported the New England Journal of Medicine online today, one day before a Congressional hearing on the safety of rosiglitazone.
Chest Pain: 10 Common Myths and Mistakes
June 1st 2007ABSTRACT: Atypical clinical presentations in the quality, intensity, and radiation of pain are common in patients with acute coronary syndromes. Women with an acute myocardial infarction (AMI) are more likely to have atypical symptoms, such as dyspnea, than men. A history of acute anxiety or a psychiatric diagnosis does not preclude the possibility of an acute coronary event in a patient with chest pain. The clinical response to a GI cocktail, sublingual nitroglycerin, or chest wall palpation does not reliably identify the source of pain. Over-reliance on tests with poor sensitivity, such as the ECG, or on the initial set of cardiac biomarkers will miss many patients with MI. Serial troponin levels obtained at 3- to 6-hour intervals are recommended to evaluate the extent of myocardial damage. Coronary angiography that detects mild non-obstructive disease does not exclude the possibility of sudden plaque rupture and acute coronary occlusion.